Zoetis Inc. (NYSE: ZTS) Stock Competitors & Peer Comparison
See ZTS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZTS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZTS | $76.29 | +0.16% | 32B | 11.59 | $6.58 | +2.73% |
| TAK | $18.71 | +1.52% | 59.5B | 13.45 | $1.39 | +3.37% |
| HLN | $9.86 | -0.50% | 43.4B | 18.39 | $0.54 | +2.01% |
| TEVA | $36.62 | -2.32% | 42.6B | 12.50 | $2.93 | N/A |
| VTRS | $16.94 | -0.88% | 19.7B | 6.72 | $2.52 | +2.83% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.42 | -1.05% | 12.2B | 23.03 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.03 | -1.11% | 10B | 19.73 | $0.61 | +0.70% |
| ALKS | $46.88 | -1.76% | 7.9B | 49.35 | $0.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ZTS vs TAK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TAK has a market cap of 59.5B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TAK trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TAK's P/E ratio is 13.45. In terms of profitability, ZTS's ROE is +0.69%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TAK's competition here
Haleon plc (NYSE: HLN)
ZTS vs HLN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while HLN trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas HLN's P/E ratio is 18.39. In terms of profitability, ZTS's ROE is +0.69%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ZTS is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ZTS vs TEVA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TEVA has a market cap of 42.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TEVA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TEVA's P/E ratio is 12.50. In terms of profitability, ZTS's ROE is +0.69%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ZTS is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ZTS vs VTRS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while VTRS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas VTRS's P/E ratio is 6.72. In terms of profitability, ZTS's ROE is +0.69%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ZTS is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ZTS vs ITCI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZTS's ROE is +0.69%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ZTS is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ZTS vs ELAN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ELAN trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ELAN's P/E ratio is 23.03. In terms of profitability, ZTS's ROE is +0.69%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ZTS is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
ZTS vs CTLT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZTS's ROE is +0.69%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ZTS is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ZTS vs RDY Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, RDY has a market cap of 10B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while RDY trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas RDY's P/E ratio is 19.73. In terms of profitability, ZTS's ROE is +0.69%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ZTS is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
ZTS vs ALKS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ALKS trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ALKS's P/E ratio is 49.35. In terms of profitability, ZTS's ROE is +0.69%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ZTS is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ZTS vs LNTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while LNTH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas LNTH's P/E ratio is 16.97. In terms of profitability, ZTS's ROE is +0.69%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZTS is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ZTS vs AMRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AMRX trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AMRX's P/E ratio is 19.86. In terms of profitability, ZTS's ROE is +0.69%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ZTS is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ZTS vs INDV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while INDV trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas INDV's P/E ratio is 9.54. In terms of profitability, ZTS's ROE is +0.69%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ZTS is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ZTS vs RGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas RGC's P/E ratio is -456.34. In terms of profitability, ZTS's ROE is +0.69%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ZTS is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
ZTS vs ALVOW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ALVOW's P/E ratio is 46.65. In terms of profitability, ZTS's ROE is +0.69%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ZTS is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ZTS vs SUPN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SUPN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SUPN's P/E ratio is 14.38. In terms of profitability, ZTS's ROE is +0.69%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ZTS is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ZTS vs BHC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas BHC's P/E ratio is 1.73. In terms of profitability, ZTS's ROE is +0.69%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ZTS is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ZTS vs HCM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while HCM trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas HCM's P/E ratio is 5.29. In terms of profitability, ZTS's ROE is +0.69%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ZTS is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ZTS vs DCPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZTS's ROE is +0.69%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ZTS is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ZTS vs AVDL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ZTS's ROE is +0.69%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ZTS is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ZTS vs TRLV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TRLV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TRLV's P/E ratio is -4.88. In terms of profitability, ZTS's ROE is +0.69%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, ZTS is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
ZTS vs PRGO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PRGO trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PRGO's P/E ratio is 5.71. In terms of profitability, ZTS's ROE is +0.69%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ZTS is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
ZTS vs EMBCV Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZTS's ROE is +0.69%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ZTS is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ZTS vs DVAX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ZTS's ROE is +0.69%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZTS is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ZTS vs ALVO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ALVO trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ALVO's P/E ratio is -15.82. In terms of profitability, ZTS's ROE is +0.69%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ZTS is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ZTS vs ETON Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ETON trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ETON's P/E ratio is 130.22. In terms of profitability, ZTS's ROE is +0.69%, compared to ETON's ROE of +0.40%. Regarding short-term risk, ZTS is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ZTS vs ANIP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ANIP trades at $71.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ANIP's P/E ratio is 8.76. In terms of profitability, ZTS's ROE is +0.69%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ZTS is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ZTS vs TARO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZTS's ROE is +0.69%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ZTS is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ZTS vs PAHC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PAHC trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PAHC's P/E ratio is 13.17. In terms of profitability, ZTS's ROE is +0.69%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ZTS is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ZTS vs HROW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while HROW trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas HROW's P/E ratio is -38.65. In terms of profitability, ZTS's ROE is +0.69%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ZTS is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
ZTS vs CRON Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CRON's P/E ratio is 30.96. In terms of profitability, ZTS's ROE is +0.69%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ZTS is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ZTS vs AMPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AMPH trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AMPH's P/E ratio is 8.14. In terms of profitability, ZTS's ROE is +0.69%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ZTS is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ZTS vs PCRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PCRX trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PCRX's P/E ratio is 10.23. In terms of profitability, ZTS's ROE is +0.69%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ZTS is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ZTS vs PETQ Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZTS's ROE is +0.69%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ZTS is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ZTS vs COLL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, COLL has a market cap of 768.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while COLL trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas COLL's P/E ratio is 2.97. In terms of profitability, ZTS's ROE is +0.69%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ZTS is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ZTS vs IRWD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas IRWD's P/E ratio is 5.50. In terms of profitability, ZTS's ROE is +0.69%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ZTS is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
ZTS vs EVO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, EVO has a market cap of 675M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas EVO's P/E ratio is -2.68. In terms of profitability, ZTS's ROE is +0.69%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ZTS is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ZTS vs AQST Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AQST has a market cap of 671.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AQST trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AQST's P/E ratio is -8.23. In terms of profitability, ZTS's ROE is +0.69%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ZTS is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AQST's competition here
Glass House Brands Inc (NYSE: GLAS)
ZTS vs GLAS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, GLAS has a market cap of 662.8M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while GLAS trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas GLAS's P/E ratio is -15.30. In terms of profitability, ZTS's ROE is +0.69%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ZTS is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
ZTS vs EOLS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, EOLS has a market cap of 596M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while EOLS trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas EOLS's P/E ratio is -28.66. In terms of profitability, ZTS's ROE is +0.69%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ZTS is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ZTS vs BDSI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZTS's ROE is +0.69%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZTS is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ZTS vs TLRY Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TLRY has a market cap of 506.6M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TLRY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TLRY's P/E ratio is -4.18. In terms of profitability, ZTS's ROE is +0.69%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ZTS is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
ZTS vs KMDA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, KMDA has a market cap of 477.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas KMDA's P/E ratio is 21.76. In terms of profitability, ZTS's ROE is +0.69%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ZTS is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ZTS vs CGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CGC has a market cap of 410.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CGC's P/E ratio is -0.59. In terms of profitability, ZTS's ROE is +0.69%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ZTS is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ZTS vs TKNO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TKNO has a market cap of 388.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TKNO trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TKNO's P/E ratio is -23.35. In terms of profitability, ZTS's ROE is +0.69%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ZTS is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ZTS vs EBS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, EBS has a market cap of 322M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while EBS trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas EBS's P/E ratio is 4.33. In terms of profitability, ZTS's ROE is +0.69%, compared to EBS's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ZTS vs ALIM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZTS's ROE is +0.69%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ZTS is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
ZTS vs LNDC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZTS's ROE is +0.69%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ZTS is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check LNDC's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ZTS vs CRDL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CRDL has a market cap of 249M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CRDL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CRDL's P/E ratio is -8.61. In terms of profitability, ZTS's ROE is +0.69%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ZTS is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CRDL's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ZTS vs ACB Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ACB has a market cap of 241M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ACB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ACB's P/E ratio is -7.94. In terms of profitability, ZTS's ROE is +0.69%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ZTS is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ZTS vs SIGA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SIGA has a market cap of 231.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SIGA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SIGA's P/E ratio is 11.96. In terms of profitability, ZTS's ROE is +0.69%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ZTS is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
ZTS vs TYHT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZTS's ROE is +0.69%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ZTS is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
ZTS vs DERM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, DERM has a market cap of 217.4M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while DERM trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas DERM's P/E ratio is -21.35. In terms of profitability, ZTS's ROE is +0.69%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ZTS is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ZTS vs ORGO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ORGO has a market cap of 211M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ORGO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ORGO's P/E ratio is 54.67. In terms of profitability, ZTS's ROE is +0.69%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ZTS is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ZTS vs REPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZTS's ROE is +0.69%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZTS is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
ZTS vs OGI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, OGI has a market cap of 164.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while OGI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas OGI's P/E ratio is 2.63. In terms of profitability, ZTS's ROE is +0.69%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ZTS is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ZTS vs LFCR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, LFCR has a market cap of 163.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while LFCR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas LFCR's P/E ratio is -4.07. In terms of profitability, ZTS's ROE is +0.69%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, ZTS is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ZTS vs THTX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas THTX's P/E ratio is -28.83. In terms of profitability, ZTS's ROE is +0.69%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ZTS is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ZTS vs ASRT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ZTS's ROE is +0.69%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ZTS is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ZTS vs SCTL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZTS's ROE is +0.69%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZTS is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ZTS vs BGM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, BGM has a market cap of 107.8M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas BGM's P/E ratio is -0.98. In terms of profitability, ZTS's ROE is +0.69%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ZTS is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ZTS vs PROC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZTS's ROE is +0.69%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZTS is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ZTS vs CPIX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CPIX's P/E ratio is -16.87. In terms of profitability, ZTS's ROE is +0.69%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ZTS is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ZTS vs OPTN Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZTS's ROE is +0.69%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ZTS is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ZTS vs ZOM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZTS's ROE is +0.69%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ZTS is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ZTS vs GRVI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZTS's ROE is +0.69%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ZTS is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ZTS vs ZYBT Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, ZTS's ROE is +0.69%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ZTS is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ZTS vs ZYNE Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ZTS's ROE is +0.69%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ZTS is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ZTS vs SSIC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZTS's ROE is +0.69%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ZTS is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
ZTS vs INCR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while INCR trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas INCR's P/E ratio is -12.23. In terms of profitability, ZTS's ROE is +0.69%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ZTS is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
ZTS vs TLPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TLPH's P/E ratio is -3.87. In terms of profitability, ZTS's ROE is +0.69%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ZTS is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ZTS vs VLNS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZTS's ROE is +0.69%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZTS is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ZTS vs DRRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ZTS's ROE is +0.69%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ZTS is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ZTS vs JUPW Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZTS's ROE is +0.69%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ZTS is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ZTS vs QLI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZTS's ROE is +0.69%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZTS is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ZTS vs CPHI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CPHI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CPHI's P/E ratio is -1.97. In terms of profitability, ZTS's ROE is +0.69%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ZTS is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ZTS vs RMTI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while RMTI trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas RMTI's P/E ratio is -5.96. In terms of profitability, ZTS's ROE is +0.69%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ZTS is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
ZTS vs HEXO Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZTS's ROE is +0.69%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZTS is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ZTS vs TXMD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, TXMD has a market cap of 25.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while TXMD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas TXMD's P/E ratio is 114.11. In terms of profitability, ZTS's ROE is +0.69%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ZTS is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ZTS vs AYTU Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AYTU's P/E ratio is -1.19. In terms of profitability, ZTS's ROE is +0.69%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ZTS is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ZTS vs CYTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZTS's ROE is +0.69%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ZTS is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ZTS vs EVOK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ZTS's ROE is +0.69%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ZTS is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ZTS vs OPTH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, OPTH has a market cap of 15.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while OPTH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas OPTH's P/E ratio is -17.24. In terms of profitability, ZTS's ROE is +0.69%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ZTS is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ZTS vs ACRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZTS's ROE is +0.69%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ZTS is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ZTS vs CABR Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, CABR has a market cap of 11.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while CABR trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas CABR's P/E ratio is -2.29. In terms of profitability, ZTS's ROE is +0.69%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ZTS is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ZTS vs AGRX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZTS's ROE is +0.69%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ZTS is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ZTS vs NLTX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZTS's ROE is +0.69%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ZTS is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check NLTX's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ZTS vs GELS Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, GELS has a market cap of 7.9M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while GELS trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas GELS's P/E ratio is -1.72. In terms of profitability, ZTS's ROE is +0.69%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ZTS is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check GELS's competition here
Lannett Company, Inc. (NYSE: LCI)
ZTS vs LCI Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZTS's ROE is +0.69%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZTS is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ZTS vs ADMP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZTS's ROE is +0.69%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZTS is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ZTS vs YCBD Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, YCBD has a market cap of 5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas YCBD's P/E ratio is -1.17. In terms of profitability, ZTS's ROE is +0.69%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ZTS is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
ZTS vs MNK Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas MNK's P/E ratio is -0.44. In terms of profitability, ZTS's ROE is +0.69%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ZTS is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ZTS vs FLGC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ZTS's ROE is +0.69%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ZTS is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ZTS vs UPC Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while UPC trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas UPC's P/E ratio is -0.54. In terms of profitability, ZTS's ROE is +0.69%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ZTS is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ZTS vs SBFM Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SBFM has a market cap of 2.6M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SBFM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SBFM's P/E ratio is -0.18. In terms of profitability, ZTS's ROE is +0.69%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ZTS is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ZTS vs PLXP Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ZTS's ROE is +0.69%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ZTS is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
ZTS vs ATNX Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ZTS's ROE is +0.69%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ZTS is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ZTS vs RDHL Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas RDHL's P/E ratio is 0.14. In terms of profitability, ZTS's ROE is +0.69%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ZTS is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ZTS vs SNOA Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SNOA's P/E ratio is -1.12. In terms of profitability, ZTS's ROE is +0.69%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ZTS is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ZTS.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ZTS vs SHPH Comparison September 2026
Zoetis Inc. (NYSE: ZTS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZTS stands at 32B. In comparison, SHPH has a market cap of 2M. Regarding current trading prices, ZTS is priced at $76.29 on the NYSE, while SHPH trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZTS currently has a P/E ratio of 11.59, whereas SHPH's P/E ratio is -0.16. In terms of profitability, ZTS's ROE is +0.69%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ZTS is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ZTS.Check SHPH's competition here